1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsProvides financial assistance to cancer patients and their caregivers to cover expenses such as transportation, housing, utilities, food, and other essential costs related to treatment.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Cancer patients undergoing treatment and their caregivers who meet income guidelines and program-specific criteria. Eligibility for some funds may require specific cancer diagnoses or age ranges (e. Confirm the full requirements in the official notice before applying.
The current listing shows varies by fund ($200 to $2,000+). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Patient Advocate Foundation Financial Aid Funds (various funds) is funded by Patient Advocate Foundation. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Platform Clinical Translation Award supports the translational development and/or early-phase clinical trials for broadly applicable clinical technologies that will address urgent and complex needs related to two congressionally directed FY26 PRMRP topic areas. The platform product in development should address one of the FY26 PRMRP portfolio-specific strategic goals and address the health care needs of military Service Members, Veterans and their Families.Distinctive Features:Allows for multiple Principal Investigators (PIs). The proposed experiments may represent a single project led by a single PI, or it may consist of partnerships between principal investigators that will occur synergistically to advance a platform product. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. Up to two additional PIs can be identified as Partnering PIs. If recommended for funding, each PI will be named on separate awards to the recipient organization(s).Requires a PI-convened external advisory board with patient advocate participation. The patient advocate must be a person living with, or a family member or caretaker of someone with, a disease or condition addressed in one of the applicant-selected congressionally directed FY26 PRMRP topic areas.Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $30M to fund approximately two Platform Clinical Translation Award applications with total cost caps of $15M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with a maximum of $8M in FY26, with the remaining budget to be funded out of future fiscal years depending upon meeting performance-based milestones and availability of future funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027. Funding Opportunity Number: HT942526PRMRPPCTA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $30M total program funding.
Summary: Initially created in fiscal year 2019 (FY19), the Kidney Cancer Research Program (KCRP) Academy of Kidney Cancer Investigators (AKCI) is a unique interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The Academy pairs Early Career Scholars (ECS) with established investigators (Designated Mentors) under the oversight of the AKCI Leadership Team, a Designated Mentor Panel, and the Kidney Cancer Patient Advocates Panel. The AKCI’s overarching goal is to conduct innovative and impactful kidney cancer research while also developing a vital resource, a network of highly productive kidney cancer researchers conducting cutting edge research that advances the state of the field in kidney cancer and leads to new treatments for individuals living with kidney cancer.Distinctive Features:· Early-Career Scholar: The FY26 KCRP AKCI-ECSA focuses on both the Scholar’sresearch and their career potential in the kidney cancer field.· Designated Mentor: The Designated Mentor must have a strong record of successful mentorship coupled with a strong record of funding (past and present) and publications in kidney cancer research.· Preliminary Data: Preliminary data to support the feasibility of the research and approaches are required; however, these data do not need to be derived from the kidney cancer research field. Funding Opportunity Number: HT942526KCRPAKCIECSA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.4M total program funding.
PCORI launched five simultaneous research funding tracks with $120 million in direct costs for pragmatic studies. Why this non-NIH funder deserves a place in your grant strategy.
Read articleARPA-H is funding the first agentic AI system that can prescribe medications, monitor patients 24/7, and manage heart disease autonomously. Here is what applicants need to know.
Read articleThe $46M FSHARP program is creating shelf-stable synthetic blood from freeze-dried components. A new SWiFT SBIR topic opened May 6 for autonomous field transfusion devices. What grant seekers in biomedical engineering need to know.
Read article